Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2022-07-17 Capital/Financing Update
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
Release of restricted securities from escrow 1 page
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement regarding the release of restricted securities from escrow, specifically shares and options becoming tradable. It references ASX Listing Rule 3.10A and details the number of securities being released and their status. The document is short (2324 characters) and is an announcement about a capital structure event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as release of restricted securities.
2022-07-17 English
Application for quotation of securities - 4DX 6 pages 27.4KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX, specifically concerning restricted securities where the escrow period has expired or is about to expire. It details the number and type of securities to be quoted, issue dates, and the status of issued capital following quotation. There is no financial performance data, earnings information, or management discussion. The document is an official announcement related to capital structure changes, specifically the quotation of securities. This fits the category of Share Issue/Capital Change (SHA). The document length is over 5,000 characters and contains substantive details about the securities quotation, not merely an announcement of a report publication or certification. Therefore, the appropriate classification is SHA with high confidence.
2022-07-17 English
Notification of cessation of securities - 4DX 4 pages 24.9KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from 4DMedical Limited regarding the cessation (lapse) of certain securities (options) due to conditions not being met. It details the number of securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The document is a regulatory announcement about changes in the company's capital structure, specifically the cessation of securities. It does not contain financial statements, management discussion, or detailed financial data. It is not a full report but an announcement of a capital change event. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content support this classification with high confidence.
2022-07-10 English
4DMedical secures national contract with I-MED 2 pages 251.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 28 June 2022, describing a new national contract between 4DMedical and I-MED Radiology Network. It details the business agreement, the scope of the contract, and the strategic significance for the company. There are no financial statements, no quarterly or annual results, no regulatory certifications, or voting results. The content is a corporate update about a contract and business development, typical of a Capital/Financing Update or business development announcement. It is not an earnings release or annual/interim report. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length is over 6,000 characters and contains substantive information about the contract, not just a brief notice or report publication announcement.
2022-06-27 English
4DMedical appoints experienced MedTech CFO 2 pages 213.7KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 24 June 2022 about the appointment of a new CFO at 4DMedical. It details the background of the incoming CFO, the outgoing CFO's transition, and includes quotes from the CEO and the new CFO. There are no financial statements, no discussion of financial results, no regulatory certifications, or report attachments. The content focuses solely on management changes at the executive level. Therefore, this document fits the category of Board/Management Information (MANG). The document length is about 4963 characters, which is consistent with a typical management announcement rather than a full report or regulatory filing.
2022-06-23 English
Board Change - Executive Appointment 2 pages 202.8KB
Board/Management Information Classification · 100% confidence The document is an announcement from 4DMedical Limited regarding a change in the company's board and management structure, specifically the appointment of a Company Director, John Livingston, to an Executive position as Senior Strategist and Executive Director. The text includes details about the appointment, remuneration, and responsibilities. There are no financial statements, earnings data, or regulatory filings referenced. The content clearly fits the category of announcing changes in the company's board or senior management rather than a report or other filing type.
2022-05-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.